CoChat

Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial

Open access

The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Xpert® MTB/RIF (Xpert) has high sensitivity for diagnosing tuberculosis (TB) compared to sputum-smear microscopy (smear) and can reduce time-to-diagnosis, time-to-treatment and potentially unfavorable patient-level treatment outcome. METHODS: People living with HIV (PLHIV) initiating antiretroviral therapy at 22 HIV clinics were enrolled and underwent systematic screening for TB (August 2012-November 2014). GeneXpert instruments were deployed following a stepped-wedge design at 13 centers from October 2012-June 2013. Treatment outcomes classified as an unfavorable outcome (died, treatment failure or loss-to-follow-up) or favorable outcome (cured and treatment completed). To determine outcome, smear was performed at month 5 or 6. Empiric treatment was defined as initiating treatment without/before receiving TB-positive results. Adjusting for intra-facility correlation, we compared patient-level treatment outcomes between patients screened using smear (smear arm)- and Xpert-based algorithms (Xpert arm). RESULTS: Among 6041 patients enrolled (smear arm, 1816; Xpert arm, 4225), 256 (199 per 2985 and 57 per 1582 person-years of follow-up in Xpert and smear arms, respectively; adjusted incidence rate ratio, 9.07; 95% confidence interval [CI]: 4.70-17.48; p < 0.001) received TB diagnosis and were treated. TB treatment outcomes were available for 203 patients (79.3%; Xpert, 157; smear, 46). Unfavorable outcomes were reported for 21.7% (10/46) in the smear and 13.4% (21/157) in Xpert arm (adjusted hazard ratio, 1.40; 95% CI: 0.75-2.26; p = 0.268). Compared to smear, in Xpert arm median days from sputum collection to TB treatment was 6 days (interquartile range [IQR] 2-17 versus 22 days [IQR] 3-51), p = 0.005; patients with available sputum test result had microbiologically confirmed TB in 59.0% (102/173) versus 41.9% (18/43), adjusted Odds Ratio [aOR], 2.00, 95% CI: 1.01-3.96, p = 0.048). In smear arm empiric treatment was 68.4% (39/57) versus 48.7% (97/199), aOR, 2.28, 95% CI: 1.24-4.20, p = 0.011), compared to Xpert arm. CONCLUSIONS: TB treatment outcomes were similar between the smear and Xpert arms. However, compared to the smear arm, more patients in the Xpert arm received a TB diagnosis, had a microbiologically confirmed TB, and had a shorter time-to-treatment, and had a lower empiric treatment. Further research is recommended to identify potential gaps in the Botswana health system and similar settings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02538952. Retrospectively registered on 2 September 2015.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12879-019-4697-5

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Enrollment*, screening by smear or by Xpert MTB/RIF, and TB diagnosis in Botswana
Fig. 1 Enrollment*, screening by smear or by Xpert MTB/RIF, and TB diagnosis in BotswanaCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 10

  1. Botswana S Botswana Aids impact survey IV (BAIS IV) 2013
  2. Botswana National Tuberculosis Program (BNTP) Manual, Ministry of Health, Botswana 2011
  3. Fielding K, Mccarthy K, Ginindza S, Chihota V, Charalambous S, Churchyard G, et al, A grant. Treatment outcome participant in the XTEND trial. Abstract OA-386-05. 46th Conference on Lung Health, Liverpool, Cape Town, South Africa 2–6 December 2015.
  4. World Health Organization Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014) 2013
  5. StataCorp Stata statistical software: release 14 2015 College Station StataCorp LP
  6. CONSORT Checklist of information to include when reporting a randomised trial 2010
  7. Auld A Agizew T Mathoma A Boyd R Date A Pals S Effect of TB screening and retention interventions on early ART mortality in Botswana. Oral abstract 31, 25th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts 2018
  8. Stop TB Partnership’s New Diagnostics Working Group/World Health Organization Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics 2009 Geneva World Health Organization
  9. The World health organization Latent tuberculosis infection Updated and consolidated guidelines for programmatic Management, WHO/CDS/TB/2018.4 2018 30277688
  10. Sun A, Denkinger C, Dowdy D. Understanding the diagnostic cascade of tuberculosis: insight from a transmission model. Abstract OAP-314-31. 45th Conference on Lung Health, Barcelona, Spain, 28 October – 1 November 2014.

Cited by

See all 18

Metadata

Authors
Agizew, T., Chihota, V., Nyirenda, S., Tedla, Z., Auld, A. F., Mathebula, U., Mathoma, A., Boyd, R., Date, A., Pals, S. L., Lekone, P., & Finlay, A.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • University of the Witwatersrand (ZA)
Corresponding author
Agizew, Tefera
Venue
BMC Infectious Diseases
Published
2019-12
Volume
19
Issue
1
Pages
1058-1058
ISSN
1471-2334 (ISSN-L)
OpenAlex
W2994745681
Cited by
17
References
18
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2022: 2 · 2021: 7
FWCI
1.73
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Infectious Diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Greater South Information System
Funders
This research has been supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention. (Not Applicable)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords
tuberculosis, HIV, Xpert MTB/RIF, sputum smear microscopy, tuberculosis treatment outcomes, tuberculosis screening, tuberculosis diagnosis, treatment failure, loss to follow-up, time to treatment, Botswana
MeSH terms
Data Accuracy, Adult, Botswana, Female, Follow-Up Studies, Humans, Male, Mass Screening, Microscopy, Mycobacterium tuberculosis, Prospective Studies, Sensitivity and Specificity, Sputum, Tuberculosis, HIV Infections, Treatment Outcome, Nucleic Acid Amplification Techniques, Lost to Follow-Up, Time-to-Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.